COSMOS Pharmaceutical (3349) Q2 2025 earnings summary

Executive summary

• Net sales for the six months ended November 30, 2024, rose 6.2% year-over-year to ¥505,936 million, with operating profit up 28.5% to ¥20,344 million and profit attributable to owners of parent up 24.5% to ¥14,428 million.

• 57 new stores were opened across multiple regions, bringing the total to 1,546 stores at period end.

Financial highlights

• Gross profit increased to ¥106,074 million from ¥92,931 million year-over-year.

• Operating profit margin improved, with operating profit at ¥20,344 million (28.5% increase year-over-year).

• Ordinary profit reached ¥21,777 million, up 25.5% year-over-year.

• Basic earnings per share were ¥182.05, reflecting a 2-for-1 stock split.

• Comprehensive income for the period was ¥14,423 million, up 24.5% year-over-year.

Outlook and guidance

• Full-year forecast for FY ending May 31, 2025: net sales ¥1,037,000 million (+7.5%), operating profit ¥31,600 million (+0.3%), ordinary profit ¥34,400 million (+0.3%), profit attributable to owners of parent ¥24,500 million (+0.2%), and basic EPS ¥309.12.

• No change to previously announced forecast.